These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 18691257)

  • 1. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
    Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
    Aplenc R; Thompson J; Han P; La M; Zhao H; Lange B; Rebbeck T
    Cancer Res; 2005 Mar; 65(6):2482-7. PubMed ID: 15781665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis.
    Bernbeck B; Mauz-Körholz C; Zotz RB; Göbel U
    Klin Padiatr; 2003; 215(6):327-31. PubMed ID: 14677097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
    Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
    Turello R; Rentsch K; Di Paolo E; Popovic MB
    Pediatr Blood Cancer; 2008 Jan; 50(1):154-6. PubMed ID: 17387702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
    Eissa DS; Ahmed TM
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.
    Kishi S; Griener J; Cheng C; Das S; Cook EH; Pei D; Hudson M; Rubnitz J; Sandlund JT; Pui CH; Relling MV
    J Clin Oncol; 2003 Aug; 21(16):3084-91. PubMed ID: 12915598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between mthfr gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia].
    Liu JX; Chen JP; Tan W; Lin DX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):488-92. PubMed ID: 18549614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.
    Chiusolo P; Reddiconto G; Farina G; Mannocci A; Fiorini A; Palladino M; La Torre G; Fianchi L; Sorà F; Laurenti L; Leone G; Sica S
    Leuk Res; 2007 Dec; 31(12):1669-74. PubMed ID: 17512587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.
    Schmeling H; Biber D; Heins S; Horneff G
    J Rheumatol; 2005 Sep; 32(9):1832-6. PubMed ID: 16142884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
    D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
    Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K
    Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study.
    Locasciulli A; Mura R; Fraschini D; Gornati G; Scovena E; Gervasoni A; Uderzo C; Masera G
    Haematologica; 1992; 77(1):49-53. PubMed ID: 1398282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.